ELOS B Stock Overview
Elos Medtech AB (publ) engages in the development and contract manufacturing of medical devices and components for dental, orthopedics, diagnostics, and hearing and other medical device markets.
No risks detected for ELOS B from our risk checks.
Elos Medtech Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr255.00|
|52 Week High||kr477.00|
|52 Week Low||kr203.00|
|1 Month Change||4.51%|
|3 Month Change||-10.84%|
|1 Year Change||18.61%|
|3 Year Change||157.06%|
|5 Year Change||193.10%|
|Change since IPO||1,600.00%|
Recent News & Updates
|ELOS B||SE Medical Equipment||SE Market|
Return vs Industry: ELOS B exceeded the Swedish Medical Equipment industry which returned -35% over the past year.
Return vs Market: ELOS B exceeded the Swedish Market which returned -23.6% over the past year.
|ELOS B volatility|
|ELOS B Average Weekly Movement||8.4%|
|Medical Equipment Industry Average Movement||8.4%|
|Market Average Movement||7.4%|
|10% most volatile stocks in SE Market||12.2%|
|10% least volatile stocks in SE Market||4.7%|
Stable Share Price: ELOS B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ELOS B's weekly volatility (8%) has been stable over the past year.
About the Company
Elos Medtech AB (publ) engages in the development and contract manufacturing of medical devices and components for dental, orthopedics, diagnostics, and hearing and other medical device markets. It offers implants, screws, plates, orthopedic and dental instruments, drills, pins and wires, dental prosthetics, disposable plastic products, and HPLC fittings, as well as other medical plastic parts. The company also provides design and development, regulatory, prototyping, testing, OEM, process validation, and supply and inventory management, as well as design for manufacturing and engineering services.
Elos Medtech Fundamentals Summary
|ELOS B fundamental statistics|
Is ELOS B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ELOS B income statement (TTM)|
|Cost of Revenue||kr476.99m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 18, 2022
|Earnings per share (EPS)||9.74|
|Net Profit Margin||10.52%|
How did ELOS B perform over the long term?See historical performance and comparison
Is ELOS B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ELOS B?
Other financial metrics that can be useful for relative valuation.
|What is ELOS B's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does ELOS B's PE Ratio compare to its peers?
|ELOS B PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: ELOS B is good value based on its Price-To-Earnings Ratio (26.2x) compared to the peer average (873.5x).
Price to Earnings Ratio vs Industry
How does ELOS B's PE Ratio compare vs other companies in the Medical Equipment Industry?
Price-To-Earnings vs Industry: ELOS B is good value based on its Price-To-Earnings Ratio (26.2x) compared to the Swedish Medical Equipment industry average (35.8x)
Price to Earnings Ratio vs Fair Ratio
What is ELOS B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||26.2x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ELOS B's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ELOS B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ELOS B's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ELOS B's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ELOS B's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Elos Medtech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Elos Medtech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Elos Medtech performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ELOS B has high quality earnings.
Growing Profit Margin: ELOS B's current net profit margins (10.5%) are higher than last year (8.5%).
Past Earnings Growth Analysis
Earnings Trend: ELOS B's earnings have grown significantly by 27.3% per year over the past 5 years.
Accelerating Growth: ELOS B's earnings growth over the past year (55.2%) exceeds its 5-year average (27.3% per year).
Earnings vs Industry: ELOS B earnings growth over the past year (55.2%) exceeded the Medical Equipment industry 6.3%.
Return on Equity
High ROE: ELOS B's Return on Equity (11.7%) is considered low.
Discover strong past performing companies
How is Elos Medtech's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ELOS B's short term assets (SEK415.6M) exceed its short term liabilities (SEK180.7M).
Long Term Liabilities: ELOS B's short term assets (SEK415.6M) exceed its long term liabilities (SEK332.4M).
Debt to Equity History and Analysis
Debt Level: ELOS B's net debt to equity ratio (31.9%) is considered satisfactory.
Reducing Debt: ELOS B's debt to equity ratio has reduced from 84.8% to 44.8% over the past 5 years.
Debt Coverage: ELOS B's debt is well covered by operating cash flow (29.6%).
Interest Coverage: ELOS B's interest payments on its debt are well covered by EBIT (15.6x coverage).
Discover healthy companies
What is Elos Medtech current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ELOS B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ELOS B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ELOS B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ELOS B's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: ELOS B is not paying a notable dividend for the Swedish market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ELOS B has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jodie Gilmore (50 yo)
Ms. Jodie Gilmore serves as President & Business Unit Director Orthopedic at Elos Medtech AB (publ) and had been Executive Vice President of Orthopedics from 2021 until 2022. She serves as Interim Chief Ex...
Experienced Management: ELOS B's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: ELOS B's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Elos Medtech AB (publ)'s employee growth, exchange listings and data sources
- Name: Elos Medtech AB (publ)
- Ticker: ELOS B
- Exchange: OM
- Founded: 1923
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: kr2.057b
- Shares outstanding: 8.07m
- Website: https://elosmedtech.com
Number of Employees
- Elos Medtech AB (publ)
- Torsgatan 5B
- Västra Götaland County
- 411 04
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.